Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1717)	10/25/2006 4:07:05 AM
From: Icebrg	Read Replies (2) \| Respond to of 1826

MGI Pharma initiated with "buy" Tuesday, October 24, 2006 11:52:09 AM ET Brean Murray, Carret & Co NEW YORK, October 24 (newratings.com) - Analyst Jonathan Aschoff of Brean Murray initiates coverage of MGI Pharma Inc (MOGN.NAS) with a "buy" rating. The target price is set to $26. In a research note published this morning, the analyst mentions that the company’s flagship drug, Aloxi, is expected to witness a recovery in 2H07, following the adverse impact of the reimbursement issue in 1H07. The Phase 3 results for MGI Pharma’s Aquavan product demonstrate the drug’s superiority to the existing market leading therapies, the analyst says. Brean Murray expresses its optimism regarding the company’s near- and long-term growth prospects.